Literature DB >> 19821522

Activation of the complement system in human nonalcoholic fatty liver disease.

Sander S Rensen1, Yanti Slaats, Ann Driessen, Carine J Peutz-Kootstra, Jeroen Nijhuis, Rudi Steffensen, Jan Willem Greve, Wim A Buurman.   

Abstract

UNLABELLED: Activation of the innate immune system plays a major role in nonalcoholic fatty liver disease (NAFLD). The complement system is an important component of innate immunity that recognizes danger signals such as tissue injury. We aimed to determine whether activation of the complement system occurs in NAFLD, to identify initiating pathways, and to assess the relation between complement activation, NAFLD severity, apoptosis, and inflammatory parameters. Liver biopsies of 43 obese subjects with various degrees of NAFLD and of 10 healthy controls were analyzed for deposition of complement factors C1q, mannose-binding lectin (MBL), C4d, activated C3, and membrane attack complex (MAC)-associated C9. Furthermore, hepatic neutrophil infiltration, apoptosis, and pro-inflammatory cytokine expression were quantified. Whereas complement activation was undetectable in the liver of healthy subjects, 74% of the NAFLD patients showed hepatic deposition of activated C3 and C4d. C1q as well as MBL accumulation was found in most activated C3-positive patients. Strikingly, 50% of activated C3-positive patients also displayed MAC-associated C9 deposition. Deposition of complement factors was predominantly seen around hepatocytes with macrovesicular steatosis. Subjects showing accumulation of activated C3 displayed increased numbers of apoptotic cells. Importantly, hepatic neutrophil infiltration as well as interleukin (IL)-8 and IL-6 expression was significantly higher in patients showing activated C3 deposition, whereas patients with C9 deposition additionally had increased IL-1beta expression. Moreover, nonalcoholic steatohepatitis (NASH) was more prevalent in patients showing hepatic C9 or activated C3 deposition.
CONCLUSION: There is widespread activation of the complement system in NAFLD, which is associated with disease severity. This may have important implications for the pathogenesis and progression of NAFLD given the function of complement factors in clearance of apoptotic cells, hepatic fibrosis, and liver regeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19821522     DOI: 10.1002/hep.23228

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  64 in total

1.  Proteome Dynamics Reveals Pro-Inflammatory Remodeling of Plasma Proteome in a Mouse Model of NAFLD.

Authors:  Ling Li; Gurkan Bebek; Stephen F Previs; Jonathan D Smith; Rovshan G Sadygov; Arthur J McCullough; Belinda Willard; Takhar Kasumov
Journal:  J Proteome Res       Date:  2016-08-05       Impact factor: 4.466

2.  Complement activation in acetaminophen-induced liver injury in mice.

Authors:  Rohit Singhal; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2012-02-07       Impact factor: 4.030

3.  The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.

Authors:  A I Musat; R M Agni; P Y Wai; J D Pirsch; D F Lorentzen; A Powell; G E Leverson; J M Bellingham; L A Fernandez; D P Foley; J D Mezrich; A M D'Alessandro; M R Lucey
Journal:  Am J Transplant       Date:  2011-03       Impact factor: 8.086

4.  Quantification of C4d deposition and hepatitis C virus RNA in tissue in cases of graft rejection and hepatitis C recurrence after liver transplantation.

Authors:  Alice Tung Wan Song; Evandro Sobroza de Mello; Venâncio Avancini Ferreira Alves; Norma de Paula Cavalheiro; Carlos Eduardo Melo; Patricia Rodrigues Bonazzi; Fatima Mitiko Tengan; Maristela Pinheiro Freire; Antonio Alci Barone; Luiz Augusto Carneiro D'Albuquerque; Edson Abdala
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-02-13       Impact factor: 2.743

5.  Complement Factor D protects mice from ethanol-induced inflammation and liver injury.

Authors:  Rebecca L McCullough; Megan R McMullen; Megan M Sheehan; Kyle L Poulsen; Sanjoy Roychowdhury; Dian J Chiang; Michele T Pritchard; Juan Caballeria; Laura E Nagy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-29       Impact factor: 4.052

Review 6.  Redox signaling and the innate immune system in alcoholic liver disease.

Authors:  Jessica I Cohen; Xiaocong Chen; Laura E Nagy
Journal:  Antioxid Redox Signal       Date:  2011-05-25       Impact factor: 8.401

7.  Dihydro-stilbene gigantol relieves CCl4-induced hepatic oxidative stress and inflammation in mice via inhibiting C5b-9 formation in the liver.

Authors:  Ya-Ru Xue; Sheng Yao; Qian Liu; Zhao-Liang Peng; Qiang-Qiang Deng; Bo Liu; Zheng-Hua Ma; Le Wang; Hu Zhou; Yang Ye; Guo-Yu Pan
Journal:  Acta Pharmacol Sin       Date:  2020-05-13       Impact factor: 6.150

8.  Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.

Authors:  Karen M Kassel; Bradley P Sullivan; Wei Cui; Bryan L Copple; James P Luyendyk
Journal:  Am J Pathol       Date:  2012-07-26       Impact factor: 4.307

9.  Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function.

Authors:  Hangeun Kim; Keith Meyer; Adrian M Di Bisceglie; Ranjit Ray
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

Review 10.  The role of the complement system in metabolic organs and metabolic diseases.

Authors:  Julia Phieler; Ruben Garcia-Martin; John D Lambris; Triantafyllos Chavakis
Journal:  Semin Immunol       Date:  2013-05-17       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.